Tallahassee, Fla., Aug. 31, 2026 /PRNewswire/ -- With more than 40 confirmed human cases of locally-acquired dengue fever in the state – including more than 30 in the Tampa Bay area - the Florida Mosquito Control Association (FMCA) is urging Floridians to take precautions and help mosquito control professionals across the state reduce the risk of mosquito borne illnesses. The confirmed cases, which prompted the Florida Department of Health in Hillsborough County to issue a mosquito-borne illness

Prenosis recognized for its AI-directed precision therapeutics platform for acute illness CHICAGO, Aug. 31, 2026 /PRNewswire/ -- Prenosis®, a biology-based technology company delivering precision therapeutics, will join fellow winners of the Chicago Innovation Awards, the Chicago region's foremost annual celebration of innovation, in New York City on Monday, August 31st to ring the Opening Nasdaq Bell. The event emphasizes the breadth of innovation in the Chicago region and shines a spotlight on

New publication demonstrates how passive, in-home monitoring may support earlier recognition of feline chronic kidney disease. ST. LOUIS, Aug. 31, 2026 /PRNewswire/ -- Purina Institute announces a new publication showing that by monitoring a cat's elimination behavior at home, it is possible to pick up subtle changes that may be associated with chronic kidney disease. This retrospective study provided additional evidence for the capabilities of a smart litter box monitor to distinguish meaningfu

前两天，礼来宣布替尔泊肽（商品名：Mounjaro），新适应症获FDA批准，用于降低高风险2型糖尿病成人患者发生主要不良心血管事件（MACE）的风险，包括心血管死亡、非致命性心脏病发作和非致命性中风。替尔泊肽成为首个获批该适应症的GLP-1R/GIPR激动剂。在爆火的GLP1赛道，替尔泊肽后来居上，销售额已经超过司美格鲁肽，称霸全球药王，现在再添这个新适应症，又打开了一片新天地，药王地位无可撼动。老规矩，我用workbuddy+摩熵MCP，调研其适应症临床进展、全球销售、中国市场情况，简单调整后，结果如下： 摩熵数据MCP已经可以接入workbuddy，目前限量开放试用，已经在用workbuddy的药圈朋友，可以联系客服，申请试用。

Company-wide oncology specialization brings more than 105 years of combined oncology experience to clinical research oversight RALEIGH, N.C., Aug. 31, 2026 /PRNewswire/ -- Sophos IRB, an independent central Institutional Review Board, today announced its launch as the first independent central IRB company dedicated to oncology, introducing a specialized model for the ethical and regulatory review of oncology clinical research. Sophos has taken a distinct approach to central IRB review by making

Third regulatory approval in less than six months enables food and beverage manufacturers to commercialize products sweetened with sweelin® in Israel. REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Amai Proteins announces that the Israeli Ministry of Health has officially approved sweelin® as a novel food ingredient for use in a broad range of food and beverage products. Food and beverage manufacturers can now formulate and commercialize products containing sweelin® in the Israeli market. The a

SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with participation from LAV, BioTrack Capital and a leading biotech fund. Prior to this round, the company raised $10 million in a seed financing round led exclusively by Qiming Venture Partners. The proceeds wil

Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving patient outcomes. - Picture is available at AP - MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- Monash Health, the largest public health service in Victoria, Australia, has signed a Memorandum of Understanding (MoU) with Data4Life, an international nonprofit digital health organization fund

Financing supports advancement of late-stage infectious disease pipeline, including Lonafarnib for the treatment of chronic hepatitis D KIRKLAND, Wash., Aug. 31, 2026 /PRNewswire/ -- EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious diseases, today announced the successful close of an oversubscribed $35 million Series A financing round. The round was led by Propel Bio Partners, with participation from Good Ventures, Arrowtow

Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly reduce overall development costs, complemented by a parallel regulatory pathway in Canada. CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage cli